| Name | Title | Contact Details |
|---|
The founder of Conval, Chester A. Siver, developed an innovative and technologically advanced line of forged steel globe valves for high pressure and high temperature steam service applications primarily for the power generation industry. In 1967, Conval was incorporated and manufacturing facilities were established in Somers, Connecticut. Conval has developed extensions to the original product line which include: • "T" and angle pattern bodies • 3500 pound and a 4500 pound series • 2 1/2, 3, and 4 inch sizes • Bellows seal valves • 3 way valves • A variety of material options • Cryogenic valves • Multiple orifice blowdown valves • Ball Valves • Nuclear Power Plant Valves Convals provides basic valve products that are durable, maintainable, and yield a low cost solution over the serviceable life of the valve. Markets for Conval include the power generation industry, refining, oil and gas production, chemical, fertilizer, and pulp industries. Besides the domestic United States market, other projected growth markets are Canada, Australia, China, Southeast Asia, Mexico, South America, and developing third world countries. Over one half of Convals sales are made internationally. Conval became a Certified ISO 9001 manufacturer in September 1992. BVQI (Bureau Veritas Quality International, N.A., Inc.) semi-annually certifies that Convals Quality Management System is in accordance with appropriate international standards for design, development, production, installation, and servicing. Also, Convals quality program meets the requirements of 10CFR50, Appendix B of the Code of Federal Regulations and ASME N Stamp for its nuclear customers, and the European Pressure Equipment Directive. Conval employs approximately 100 employees working on two shifts. Convals operations consist of the machining of most parts used to assemble finished valves, the maintenance of adequate parts inventory to support production, and the development of new valve products.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.